동물용 자가면역질환 치료제 시장 : 치료법별, 질환별, 동물 유형별, 유통 채널별, 세계 예측(2023-2032년)

Global Veterinary Autoimmune Disease Therapeutics Market will witness over 5.3% CAGR between 2023 and 2032. The rising incidence of autoimmune diseases in animals, including dogs and cats, propels the demand for effective treatments. Increasing pet ownership and the deepening bond between humans and their pets contribute to a willingness to invest in advanced treatments.

For instance, according to a Forbes report from June 2023, pet ownership in the United States reached 66%, encompassing 86.9 million households-an increase from 56% recorded in 1988. These statistics prove the enduring significance of pets in people's lives. For many, pets provide companionship and emotional support, with 85% of dog owners and 76% of cat owners considering their furry friends as integral family members. Advancements in veterinary medicine and diagnostics are expanding treatment options. Additionally, the growing awareness of autoimmune conditions in animals fosters veterinary autoimmune disease therapeutics market growth.

The overall Veterinary Autoimmune Disease Therapeutics Market is classified based on therapy, disease, and region.

The azathioprine segment will undergo significant development from 2023 to 2032. Azathioprine is a crucial immunosuppressive drug used to manage autoimmune disorders in animals. Its efficacy in controlling excessive immune responses and alleviating symptoms like inflammation and organ damage makes it a sought-after treatment option in veterinary autoimmune disease therapeutics, contributing significantly to veterinary autoimmune disease therapeutics market demand.

The pemphigus disease segment will register a commendable CAGR from 2023 to 2032. Pemphigus is an autoimmune condition that affects pets, leading to painful skin and mucous membrane lesions. Veterinary autoimmune disease therapeutics, including medications like corticosteroids and immunosuppressants, are in demand to manage and alleviate the symptoms of pemphigus, improving the quality of life for affected animals and driving veterinary autoimmune disease therapeutics market revenue.

Europe veterinary autoimmune disease therapeutics market will showcase an appreciable CAGR from 2023 to 2032. The region's deep-rooted affection for pets, stringent animal welfare standards, and advanced veterinary care infrastructure drive the need for autoimmune disease therapeutics. Increasing efforts from countries to curb the mistreatment of animals support market growth in the region. For instance, according to news from June 2022, French lawmakers passed an amendment to the Act on the Treatment of Animals in November 2021. According to this amendment, pet stores will be prohibited from exhibiting and selling dogs and cats starting in 2024.

In addition, the public will no longer be permitted to conduct online transactions involving dogs and cats. The regulation intends to combat the escalating issue of pet abandonment, which witnessed an increase during the COVID-19 pandemic. With increasing awareness of pet health and autoimmune conditions, Europe remains a significant market for veterinary autoimmune disease treatments, supporting the well-being of beloved companion animals across the continent.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.4 Covid-19 impact analysis at global level
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Secondary
    • 1.6.1.1 Paid sources
    • 1.6.1.2 Public sources
  • 1.6.2 Primary

Chapter 2 Executive Summary

• 2.1 Veterinary Auto-immune Therapeutics Market 360 degree Synopsis, 2018 - 2032
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Therapy type trends
  • 2.1.4 Disease trends
  • 2.1.5 Animal type trends
  • 2.1.6 Distribution channel trends

Chapter 3 Veterinary Auto-immune Therapeutics Market Industry Insights

• 3.1 Industry landscape, 2018 - 2032 (USD Million)
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing threat of transfer of zoonotic diseases among humans
    • 3.2.1.2 Rising incidence of auto-immune diseases in livestock animals
    • 3.2.1.3 Increasing awareness and diagnosis of autoimmune diseases
    • 3.2.1.4 Increasing companion animal ownership
    • 3.2.1.5 Increasing expenditure on animal healthcare
    • 3.2.1.6 Increasing in animal health medicalization rate
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of veterinary auto-immune therapies
    • 3.2.2.2 Increase risk of infection due to auto-immune drugs
• 3.3 Growth potential analysis
  • 3.3.1 By therapy type
  • 3.3.2 By disease
  • 3.3.3 By animal type
  • 3.3.4 By distribution channel
  • 3.3.5 By Region
• 3.4 COVID-19 impact analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Global company market share analysis, 2022
• 4.4 Competitive positioning matrix, 2022
• 4.5 Strategic dashboard, 2022

Chapter 5 Veterinary Auto-immune Therapeutics Market Size and Forecast, By Therapy Type (USD Million)

• 5.1 Key trends, by therapy type
• 5.2 Corticosteriods
• 5.3 Azathioprine
• 5.4 Cyclosporine
• 5.5 Mycophenolate
• 5.6 Leflunomide
• 5.7 Cyclophosphamide
• 5.8 Levothyroxine
• 5.9 Folic acid
• 6.10 Hydroxychloroquine
• 6.11 Chloroquine

Chapter 6 Veterinary Auto-immune Therapeutics Market Size and Forecast, By Disease (USD Million)

• 6.1 Key trends, by disease
• 6.2 Hypothyroidism
• 6.3 Pemphigus disease
• 6.4 Canine lupus
• 6.5 Auto-immune haemolytic anaemia
• 6.6 Bullous pemphigoid
• 6.7 Discoid lupus erythematosus (DLE)
• 6.8 Immune-related arthritis
• 6.9 Other diseases

Chapter 7 Veterinary Auto-immune Therapeutics Market Size and Forecast, By Animal Type (USD Million)

• 7.1 Key trends, by animal type
• 7.2 Companion animals
  • 7.2.1 Dogs
  • 7.2.2 Cats
  • 7.2.3 Horses
  • 7.2.4 Other companion animals
• 7.3 Livestock animals
  • 7.3.1 Cattle
  • 7.3.2 Swine
  • 7.3.3 Poultry
  • 7.3.4 Sheep
  • 7.3.5 Other livestock animals
• 7.4 Other animals

Chapter 8 Veterinary Auto-immune Therapeutics Market Size and Forecast, By Distribution Channel (USD Million)

• 10.1 Key trends, by distribution channel
• 10.2 Veterinary hospitals
• 10.3 Veterinary clinics

Chapter 9 Veterinary Auto-immune Therapeutics Market Size and Forecast, By Country (USD Million)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East & Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

• 12.1 Aratana Therapeutics, Inc.
• 12.2 Pfizer Inc.
• 12.3 Vet-Stem, Inc.
• 12.4 Ambrx, Inc.
• 12.5 Taconic Biosciences, Inc.
• 12.6 JBS United
• 12.7 Virbac
• 12.8 Eli Lily and Company
• 12.9 Jaguar Animal Health Inc.